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The reduced risk of epithelial ovarian cancer associated with
parity and oral contraceptive use suggests that pituitary and/or
ovarian hormones or ovulatory events are important in the aeti-
ology of these tumours (Cramer, 1986). Nevertheless, despite
extensive study, the influence of menstrual and reproductive
factors, with the exception of parity, remains uncertain. In this
report, we evaluate menstrual and reproductive characteristics in
relation to ovarian cancer risk overall, and in relation to the major
tumour histologic subtypes. Our findings are considered in light of
several current hypotheses regarding ovarian cancer pathogenesis.
Briefly, the incessant ovulation hypothesis suggests that risk is
increased by chronic post-ovulatory trauma to the epithelial
surface of the ovary, and the tendency to form inclusion cysts
(Fathalla, 1971; Casagrande et al, 1979). The gonadotrophin
hypothesis proposes that excessive gonadotropin secretion and
consequent increases in oestrogen stimulation lead to proliferation
and malignant transformation of ovarian epithelium (Cramer,
1983). More recent hypotheses have suggested a role for chronic
ovarian inflammation (Ness, 1999), androgens and progesterone
(Risch, 1998), and the possibility that pregnancies reduce risk by
clearing transforming cells from the ovaries (ovarian clearance)
(Adami et al, 1994). 
METHODS 
We conducted a population-based, case-control study of epithelial
ovarian cancer in eastern Massachusetts (MA) and New Hampshire
(NH). The methods used have been previously described (Cramer
et al, 1998; Harlow et al, 1998). Briefly, 1033 potentially eligible
case women (ages 20 to 74) were ascertained between May 1992
and March 1997 through state-wide cancer registries (NH, MA)
and hospital tumour boards (MA). After exclusion of patients who
had nonepithelial tumours (n = 52), and those who had died (n =
91), moved out of state (n = 27), had no telephone (n = 24), or did
not speak English (n = 14), 825 case women were eligible for the
study. Physicians denied permission to contact 126 (14%) of these
women, and 136 (16%) of women declined to participate. This
analysis is based on 563 cases of epithelial ovarian cancer,
including lesions of borderline malignancy. 
Control women were identified primarily by random digit
dialing (RDD) (Waksberg, 1978), and matched to case women by
age (within 4 years) and telephone sampling unit. Of approx-
imately 5400 residential households contacted, 10% declined to
provide a household census, and 80% provided a census, but
lacked a potentially eligible control subject. In the remaining 10%
of households, a potentially eligible control was identified. 72% of
the potential control women agreed to participate in the study. In
MA, control women of age 60 or older were randomly chosen
from Town Books, and matched to case women by age and
precinct. Of 328 control women selected from Town Books, 21%
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could not be reached, 18% were ineligible, and 30% declined to
participate. Women who reported a bilateral oophorectomy were
ineligible for participation. The present analyses are based on a
total of 523 RDD and Town Book control women. 
We conducted in-person interviews at the homes of case and
control study participants. The questionnaire elicited demographic
characteristics, lifestyle factors, dietary patterns, menstrual and
reproductive history, and personal and family medical history.
Reproductive variables of interest included parity, age at first
birth, age at last birth, time elapsed since the last birth, total
number of childbearing years (time elapsed between the first and
last birth), and breast-feeding (ever/never, average duration in
months per breast-fed child). We also evaluated specific birth
outcomes, including abortion, miscarriage, stillbirth, preterm
singleton live birth, full term singleton live birth, and twin birth in
relation to ovarian cancer risk. Menstrual factors of interest were
age at menarche, age at natural menopause, the number of months
elapsed from menarche until menstrual cycle regularization
(cycles predictable within 10 days), usual menstrual cycle length
in days, usual number of days of menstrual bleeding, usual amount
of menstrual bleeding, and sanitary products usually used between
ages 20 and 40 (tampons, napkins). We evaluated menstrual
symptoms, including usual level of menstrual pain/cramping,
tension/mood swings, depression/inability to cope, sweats/hot
flashes, headaches, insomnia, weight gain/bloating/swelling, back
aches/muscle or joint pain, and breast pain, in relation to risk.
Menstrual and reproductive factors were also assessed (using
dichotomous cutpoints) in relation to the major tumour histologic
subtypes (serous borderline, serous invasive, mucinous, and
endometrioid/clear cell). In general, tumour type was determined
by a review of the pathology report; for ambiguous diagnoses
(5%), we obtained microscopy slides for review by our study
pathologist. 
We used unconditional logistic regression models to generate odds
ratios and 95% confidence intervals for risk factors in relation to
ovarian cancer occurrence, and in relation to the major tumour histo-
logic subtypes (Breslow and Day, 1980). Variables were treated as
continuous in likelihood ratio tests of linear trend when appropriate.
The analyses considered only the exposures occurring prior to the
date of diagnosis for case women and one year prior to interview for
control women. We found no evidence of confounding by education,
body mass index (kg/m2), marital status, religion, family history of
ovarian or breast cancer (in mother or sisters), history of infertility
(unable to conceive for ³2 years), history of tubal ligation, perineal
talc use, or oral contraceptive use. We have therefore mainly
presented results adjusted for age, state (MA, NH), and parity (0, 1, 2,
3, 4, ³5). The analyses of twin births and adverse birth outcomes
were adjusted for age, state, and the number of full term singleton live
births (0, 1, 2, -³3). Stratified analyses, generally adjusted for age,
state and parity, were undertaken to evaluate potential effect modifi-
cation by menopausal status (premenopausal, postmenopausal), and
by oral contraceptive use (never, ever). Likelihood ratio tests were
used to examine the statistical significance of interactions. Women
with unknown menopausal status (n = 171) were excluded from the
analyses of age at menopause in relation to ovarian cancer risk, and
from the analyses stratified by menopausal status. 
RESULTS 
Case women were less likely than control women to have ever
married, and more likely to report a family history of ovarian
cancer (Table 1); they also reported lower levels of education, and
less use of oral contraceptives. 
Relative to nulliparous women, parous women had a statist-
ically significant reduction of ovarian cancer risk (OR = 0.4; 95%
CI = 0.3–0.6) (Table 2). Among parous women, increased parity
was inversely associated with risk (P for trend = 0.0006). Women
with one birth had a 40% reduced risk; risk was reduced by 80%
for those with 5 or more births. 
In an analysis restricted to parous women, ovarian cancer risk
decreased significantly with increasing age at first birth (P for
trend = 0.03) (Table 2). The finding pertained to uniparous
women, and to women who had at least two births (data not
shown). Stratified analyses indicated that the lower risk associ-
ated with later age at first birth (³25 vs. <25 years) was
observed only in women who had used oral contraceptives, and
Table 1 Distribution of case and control women by select factorsa
Factor Cases n = 563 Controls n = 523
number (%) number (%) 
Age 
<30 29 (5.2) 37 (7.1) 
30–39 78 (13.9) 89 (17.0) 
40–49 159 (28.2) 136 (26.0) 
50–59 126 (22.4) 118 (22.6) 
60–69 118 (21.0) 117 (22.4) 
³70 53 (9.4) 26 (5.0) 
State 
MA 435 (77.3) 411 (78.6) 
NH 128 (22.7) 112 (21.4) 
Marital status 
Never married 110 (19.5) 61 (11.7) 
Ever married 453 (80.5) 462 (88.3) 
Education 
Less than high school 58 (10.3) 30 (5.7) 
High school graduate 160 (28.4) 141 (27.0) 
Post-high school 144 (25.6) 152 (29.1) 
College graduate 201 (35.7) 200 (38.2) 
Family history of ovarian cancerb
No 528 (94.3) 505 (97.3) 
Yes 32 (5.7) 14 (2.7) 
Family history of breast cancerb
No 500 (89.3) 469 (90.2) 
Yes 60 (10.7) 51 (9.8) 
Religion 
Non-Jewish 509 (90.4) 479 (91.6) 
Jewish 54 (9.6) 44 (8.4) 
Body mass index 
<20 65 (11.5) 55 (10.5) 
20.00–22.49 115 (20.4) 134 (25.7) 
22.50–24.99 137 (24.3) 124 (23.8) 
25.00–27.49 81 (14.4) 78 (14.9) 
27.50–29.99 59 (10.5) 50 (9.6) 
³30 106 (18.8) 81 (15.5) 
Oral contraceptive use (months) 
0 312 (55.4) 236 (45.1) 
1–12 98 (17.4) 81 (15.5) 
13–60 80 (14.2) 106 (20.3) 
³61 73 (13.0) 100 (19.1) 
History of infertilityc
No 365 (80.6) 376 (81.4) 
Yes 88 (19.4) 86 (18.6) 
History of tubal ligation 
No 488 (86.7) 437 (83.6) 
Yes 75 (13.3) 86 (16.4) 
a Variations in column totals are due to missing values. b Ovarian or breast
cancer in mother or sister. c Among ever married women. 716 L Titus-Ernstoff et al
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in those whose ovarian cancer occurred before menopause; the
statistical tests for interaction with oral contraceptive use (P =
0.05) and menopausal status (P = 0.002) were both significant.
Further analyses indicated that the association between later age
at first birth and reduced risk was confined to women who had
used oral contraceptives and whose ovarian cancer was diag-
nosed before menopause (OR = 0.4; 95% CI = 0.2–0.7). Because
of small numbers, we were unable to determine whether the
reduced risk was more pronounced in women who had used oral
contraceptives before their first birth, but the duration of oral
contraceptive use was not correlated with age at first birth
(r = 20.04; P = 0.46). 
Risk decreased significantly with increasing age at last birth
(P for trend = 0.05) (Table 2). However, relative to a last birth
between ages 25–29, there was no additional benefit associated
with a last birth at age 30 or later. Among women with at least two
births, age at first and last birth were moderately correlated (r =
0.53, P < 0.001), and neither factor was significantly related to
ovarian cancer risk when mutually adjusted. Risk increased with a
related factor, the amount of time elapsed since the last birth (P for
trend = 0.04). There was no evidence that the total number of
childbearing years was related to risk (for each year, OR = 1.00;
95% CI = 0.95–1.05). 
Among women with at least one live birth, ever having breast-
fed was associated with a statistically significant reduction in risk
(OR = 0.7; 95% CI = 0.5–1.0) (Table 2). Breast-feeding for
an average of 3–6 months, compared to never breast-feeding,
was associated with a 30% decreased risk (OR = 0.7; 95%
CI = 0.5–1.1). There was no additional benefit with a longer
average duration of breast-feeding, and the test for trend was non-
significant (P = 0.21). The total duration of breast-feeding was
also unrelated to risk (P for trend = 0.34). 
Most adverse pregnancy outcomes, including abortion, miscar-
riage, and stillbirth were unrelated to risk, although power was
limited to evaluate the stillbirths (Table 3). A history of either a
preterm (OR = 0.7; 95% CI = 0.4–1.0) or full-term singleton live
birth (OR = 0.4; 95% CI = 0.3–0.6) was associated with a reduced
risk. A history of twin birth appeared to be associated with
Table 2 Distribution of case and control women by reproductive factors; odds ratios (OR) and 95% confidence intervals
(CI) for the relationship with ovarian cancer risk. 
Reproductive factor Cases number (%) Controls number (%) OR (95% CI)a
Parity 
Nulliparous 185 (32.9) 106 (20.3) 1.0– 
Parous 378 (67.1) 417 (79.7) 0.4 (0.3–0.6) 
1 74 (13.1) 63 (12.0) 0.6 (0.4–0.9) 
2 132 (23.4) 143 (27.3) 0.4 (0.3–0.6) 
3 90 (16.0) 107 (20.5) 0.3 (0.2–0.5) 
4 50 (8.9) 59 (11.3) 0.3 (0.2–0.5) 
³5 32 (5.7) 45 (8.6) 0.2 (0.1–0.4) 
P for trendb 0.0006 
Age at first birthb
<20 46 (12.2) 50 (12.0) 1.2 (0.8–1.9) 
20–24 (referent) 173 (45.8) 180 (43.2) 1.0– 
25–29 105 (27.8) 130 (31.2) 0.8 (0.6–1.1) 
³30 54 (14.3) 57 (13.7) 0.9 (0.6–1.4) 
P for trend 0.03 
Age at last birthb
<25 69 (18.3) 53 (12.7) 1.6 (1.0–2.5) 
25–29 (referent) 119 (31.5) 139 (33.3) 1.0– 
30–34 110 (29.1) 130 (31.2) 1.0 (0.7–1.5) 
³35 80 (21.2) 95 (22.8) 1.0 (0.6–1.5) 
P for trend 0.05 
Years since last birthb
<10 42 (11.1) 94 (22.5) 0.6 (0.3–1.1) 
10–19 79 (20.9) 74 (17.7) 1.3 (0.8–2.0) 
20–29 (referent) 140 (37.0) 152 (36.5) 1.0– 
³30 117 (31.0) 97 (23.3) 1.0 (0.6–1.6) 
P for trend 0.04 
Breast-feedingc
Never 239 (63.2) 223 (53.5) 1.0– 
Ever 139 (36.8) 194 (46.5) 0.7 (0.5–1.0) 
Average duration breast-feeding (months)d
<3 43 (11.4) 48 (11.5) 0.9 (0.6–1.4) 
3–6 54 (14.3) 76 (18.2) 0.7 (0.5–1.1) 
>6 42 (11.1) 70 (16.8) 0.7 (0.4–1.0) 
P for trende 0.21 
a OR for parity adjusted for age and state, all other ORs adjusted for age, state, and parity. b Among parous women. 
c Among women with at least one live birth. d Average duration (months) per breast-fed child, relative to not breast-feeding
any child. e Among women who breast-fed. decreased risk (OR = 0.6; 95% CI = 0.3–1.2), but the finding
was not statistically significant. The findings in Table 3 were
unchanged when further adjusted for all other birth outcomes, and
when the analyses were restricted to gravid women (data not
shown). 
We also evaluated menstrual factors in relation to ovarian
cancer risk. Menarcheal age was unrelated to risk overall (P
for trend = 0.38), although menarche at age 16 or more, relative
to age 13, appeared to be associated with a decreased risk
(Table 4). Age at menarche was inversely associated with
risk among premenopausal women (P for trend = 0.02), and
the interaction between menopausal status and menarcheal
age was statistically significant (P = 0.002). Among
premenopausal women, menarche at age 16 years or more,
relative to before age 16, was associated with a marginally
significant reduced risk (OR = 0.5; 95% CI = 0.2–1.0). Age at
Ovarian cancer risk 717
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Table 4 Distribution of case and control women by menstrual factorsa; odds ratios (OR) and 95% confidence intervals (Cl) for the relationship with ovarian
cancer risk 
Menstrual factor Cases number (%) Controls number (%) OR (95% CI)b
Age at menarche 
<11 36 (6.4) 33 (6.3) 1.1 (0.7–1.9) 
11–12 218 (38.8) 198 (37.9) 1.0 (0.7–1.3) 
13 (referent) 175 (31.1) 155 (29.7) 1.0– 
14–15 108 (19.2) 99 (19.0) 1.0 (0.7–1.5) 
³16 25 (4.4) 37 (7.1) 0.6 (0.4–1.1) 
P for trend 0.38 
Age at natural menopause 
<45 35 (15.5) 28 (14.4) 1.1 (0.6–2.0) 
45–49 69 (30.5) 55 (28.4) 1.2 (0.7–1.9) 
50–54 (referent) 97 (42.9) 92 (47.4) 1.0– 
³55 25 (11.1) 19 (9.8) 1.4 (0.7–2.7) 
P for trend 0.71 
Months until menstrual cycle regularization 
0 (referent) 461 (81.9) 418 (79.9) 1.0– 
1–12 18 (3.2) 21 (4.0) 0.8 (0.4–1.6) 
13–60 17 (3.0) 15 (2.9) 1.2 (0.6–2.4) 
³61 18 (3.2) 16 (3.1) 1.1 (0.5–2.2) 
never regular 49 (8.7) 53 (10.1) 0.8 (0.6–1.3) 
P for trendc 0.65 
Menstrual cycle length (days) 
<27 74 (13.2) 64 (12.2) 1.0 (0.7–1.4) 
27–29 (referent) 330 (58.8) 289 (55.3) 1.0– 
³30 106 (18.9) 118 (22.6) 0.8 (0.6–1.1) 
never regular 51 (9.1) 52 (9.9) 0.9 (0.6–1.3) 
P for trendc 0.45
Days of menstrual bleeding 
<4 52 (9.3) 52 (9.9) 0.9 (0.6–1.3) 
4 91 (16.2) 100 (19.1) 0.8 (0.5–1.1) 
5 (referent) 243 (43.3) 207 (39.6) 1.0– 
6 71 (12.7) 69 (13.2) 0.9 (0.6–1.3) 
³7 104 (18.5) 95 (18.2) 1.0 (0.7–1.4) 
P for trend 0.55 
Amount of menstrual bleeding 
light 34 (6.1) 34 (6.8) 0.8 (0.5–1.3) 
moderate (referent) 294 (52.4) 239 (47.7) 1.0– 
moderately heavy 137 (24.4) 143 (28.5) 0.7 (0.6–1.0) 
heavy 96 (17.1) 85 (17.0) 0.9 (0.6–1.3) 
P for trend 0.50 
Sanitary productd
pads (referent) 282 (70.7) 219 (67.8) 1.0– 
tampons 117 (29.3) 104 (32.2) 0.9 (0.6–1.3) 
a Variations in column totals are due to missing values. b Adjusted for age, state, parity. c Among women whose menstrual periods became regular. d Women
who reported using both types of products were excluded from this analysis. 
Table 3 Number and percent of case and control women reporting specific
birth outcomes, odds ratios (OR), and 95% confidence intervals (CI) for the
relationship with ovarian cancer risk 
Pregnancy outcomeb Cases Controls OR (95% CI)a
number (%) number (%)
Abortion 64 (11.4) 56 (10.7) 1.1 (0.7–1.6) 
Miscarriage 136 (24.2) 139 (26.6) 1.0 (0.7–1.3) 
Stillbirth 12 (2.1) 10 (1.9) 1.2 (0.5–2.9) 
Preterm live birth 41 (7.3) 49 (9.4) 0.7 (0.4–1.0) 
Term live birth 366 (65.1) 403 (77.1) 0.4 (0.3–0.6) 
Twin birth 11 (2.0) 17 (3.3) 0.6 (0.3–1.2) 
aTerm live birth adjusted for age and state, all other pregnancy outcomes
adjusted for age, state, and full term live singleton birth (0, 1, 2, > 3). 
bReference group is women who did not have this birth outcome. natural menopause was not related to ovarian cancer risk (P for
trend = 0.71). 
The amount of time elapsed between menarche and menstrual
cycle regularization (P for trend = 0.65), menstrual cycle length (P
for trend = 0.44), the number of days of menstrual bleeding (P for
trend = 0.55), and the amount of menstrual bleeding (P for trend =
0.50) were unrelated to ovarian cancer risk (Table 4). We also
found no indication that risk was influenced by the type of sanitary
product used during menstruation. 
Most menstrual symptoms were unrelated to risk (Table 5), but
cycle-related insomnia was associated with a significantly
decreased risk (OR = 0.5; 95% CI = 0.3–0.8). 
We examined key reproductive and menstrual factors (using
dichotomous cutpoints) in relation to the major histologic subtypes
(Table 6). Parous women, compared to nulliparous women, had a
strong (60%) and significantly reduced risk of all the tumour
subtypes. Increasing parity was significantly associated with
reduced risk of serous invasive (P for trend = 0.003) and
endometrioid/clear cell tumours (P for trend = 0.002). An apparent
inverse association between parity and serous borderline tumours
(data not shown) was not statistically significant. There was no
evidence, among parous women, that increasing parity was associ-
ated with risk of mucinous tumours. 
Relative to a first birth before age 25, a first birth at a later age
was associated with a significant (60%) reduced risk of serous
borderline tumours, and a marginally significant (40%) decreased
risk of endometrioid/clear cell tumours; increasing age at first birth
was significantly associated with a decreased risk of these tumour
types (Table 6). Increasing age at last birth was significantly associ-
ated with decreased risk of endometrioid/clear cell tumours (P for
trend = 0.0009). Ever having breast-fed was associated with a
significant (60%) reduction in risk of endometrioid/clear cell
tumours; risk of this subtype also decreased with a longer average
duration of breast-feeding (P for trend = 0.04). Breast-feeding was
not related to risk of the other subtypes. 
Menarche at age 16 or later, relative to before age 16, was associ-
ated with a significant (90%) decreased risk of endometrioid/clear
cell tumours, but there was no evidence of linear trend, and
menarcheal age was unrelated to other tumour subtypes. Age at
menopause was not associated with risk of any tumour subtype. 
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Table 5 Distribution of case and control women by menstrual symptomsa, odds ratios (OR) and 95% confidence
intervals (Cl) for the relationship with ovarian cancer risk 
Menstrual symptom Cases number (%) Controls number (%) OR (95% CI)b
Menstrual pain/cramping 
no pain (referent) 148 (26.4) 148 (28.3) 1.0– 
mild pain 201 (35.8) 209 (40.0) 0.9 (0.7–1.3) 
moderate/severe pain 212 (37.8) 166 (31.7) 1.2 (0.8–1.6) 
P for trend 0.31 
Other menstrual symptomsc
tension/mood swings 303 (54.0) 302 (60.3) 0.8 (0.6–1.1) 
depression/inability to cope 115 (20.5) 124 (24.8)  0.8 (0.6–1.1) 
sweats/hot flushes 59 (10.5) 45 (9.0) 1.3 (0.8–1.9) 
headaches 175 (31.2) 182 (36.3) 0.8 (0.6–1.1) 
insomnia 46 (8.2) 74 (14.8) 0.5 (0.3–0.8) 
weight gain/bloating/swelling 385 (68.6) 352 (70.3)  1.0 (0.7–1.3) 
backaches/muscle or joint pain 261 (46.5) 237 (47.3)  1.0 (0.8–1.3) 
breast pain 286 (51.0) 262 (52.3) 1.0 (0.8–1.3) 
a Variations in column totals are due to missing values. b Adjusted for age state, and parity. c Number and percent of
women reporting these symptoms, reference category is not reporting this symptom. 
Table 6 Odds ratiosa (OR) and 95% confidence intervals (Cl) for the relation of select menstrual and reproductive factors to risk of the major tumor histologic
subtypes 
Risk factor Serous borderline (86 cases)  Serous Invasive (229 cases) Mucinous (83 cases) Endometrioid/clear  cell  (130  cases)
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Parousb 0.4 (0.3–0.7) 0.4 (0.3–0.7) 0.4 (0.2–0.7) 0.4 (0.2–0.6) 
P for trendc 0.20 0.003 0.81 0.002 
Age ³ 25 at first birthc 0.4 (0.2–0.9) 1.0 (0.6–1.4) 0.9 (0.5–1.7) 0.6 (0.4–1.0) 
P for trendc 0.02 0.52 0.65 0.006 
Age ³ 30 at last birthc 0.8 (0.4–1.6) 1.0 (0.7–1.5) 1.1 (0.6–2.0) 0.7 (0.4–1.1) 
P for trendc 0.11 0.89 0.39 0.0009 
Ever breastfedd 0.8 (0.4–1.6) 1.0 (0.6–1.4) 0.6 (0.3–1.2) 0.4 (0.2–0.7) 
P for trende 0.61 0.34 0.88 0.04 
Menarcheal age ³ 16 1.0 (0.4–2.4) 0.6 (0.3–1.3) 1.3 (0.6–3.2) 0.1 (0.0–0.8) 
P for trend 0.59 0.30 0.60 0.59 
Age at menopause <50 1.9 (0.5–7.6) 0.9 (0.6–1.5) 1.8 (0.7–4.6) 0.9 (0.5–1.7) 
P for trend 0.76 0.41 0.32 0.48 
a Variables (other than parous) adjusted for age, state, parity. b Adjusted for age, state; reference is nulliparous. c Among parous women. d Among women who
had at least one live birth. e Average duration (months) per breast-fed child. Ovarian cancer risk 719
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DISCUSSION 
The strong and consistently observed risk reduction associated
with parity provides, in part, the basis of most hypotheses
regarding ovarian pathogenesis. It has been shown, however, that
interruption of ovulation during pregnancy, lactation, and oral
contraceptive use is inadequate to account for the magnitude of the
observed decrease in ovarian cancer risk (Risch et al, 1983); sim-
ilarly, it seems unlikely that the suspension of ovulation-induced
inflammation or changes in hormone levels would fully account
for the observed risk reduction. Moreover, none of the existing
hypotheses adequately explains the substantial reduction of risk
associated with one birth event. A full or near-term pregnancy may
induce a permanent change in pituitary-mediated hormonal
production, or cause a decidual reaction that decreases the suscept-
ibility of the ovarian and pelvic surface epithelium to malignant
transformation (Cramer, 1999). 
In this study, late age at first birth was associated with reduced
risk, although the effect was observed only in women who had
used oral contraceptives and whose ovarian cancer was diagnosed
before menopause. A few previous studies (Purdie et al, 1995),
including the collaborative analysis of 12 population-based
studies (Whittemore et al, 1992) also noted an inverse relation-
ship between age at first birth and risk, but most found no associ-
ation (for example, Risch et al, 1994), or an increased risk (for
example, Negri et al, 1991). In contrast to previous studies (Risch
et al, 1994; Salazar-Martinez et al, 1999), we also found a signi-
ficant association between increasing age at last birth and reduced
risk. Our evaluation of a related variable, the number of years
since last birth, showed that risk increased with greater time
elapsed since the woman’s last birth. In contrast to a previous
study (Godard et al, 1998), we found no evidence that the total
number of childbearing years was associated with ovarian cancer
risk. 
Menstrual cycles occurring between ages 25 and 39 are most
likely to be ovulatory (Harlow and Ephross, 1995), and pregnan-
cies occurring between these ages have a greater potential to inter-
rupt ovulatory cycles. Thus, our observation of reduced risk
associated with later ages at first or last birth provides some
support for hypotheses regarding incessant ovulation or ovarian
inflammation. Pituitary secretion of gonadotropins generally
increases during adulthood, but decreases during pregnancy; thus,
the protective effects of later childbirth are also consistent with the
gonadotropin hypothesis. The decreasing risk associated with later
age at last birth is also consistent with the ovarian clearance
hypothesis, and in particular with the notion that the protective
‘clearance’ effect of pregnancy is greater in older women, who are
more likely to have premalignant ovarian epithelial cells (Adami
et al, 1994). 
Our finding that adverse birth outcomes, including pregnancy
losses, were not significantly associated with ovarian cancer risk is
consistent with most (for example, Hartge et al, 1989; Chen et al,
1992; Polychronopoulou et al, 1993), but not all previous studies
(for example, Whittemore et al, 1988; Negri et al, 1991). The
reduced risk observed in association with preterm, full term, or
twin births is consistent with the protective effect of parity.
Gonadotropins are generally higher among the mothers of dizygotic
twins, relative to mothers of singletons (Thomas et al, 1998), but we
were unable to distinguish dizygotic from monozygotic twin births. 
In this study, and in most previous reports (Gwinn et al, 1990;
Rosenblatt et al, 1993; Whittemore, 1993), breast-feeding was
associated with reduced risk. Consistent with some previous
studies (Rosenblatt et al, 1993; Whittemore, 1993; Salazar-
Martinez et al, 1999), but not all (Gwinn et al, 1990), we found no
relation between risk and duration of breast-feeding. Ovulatory
cycles may resume in conjunction with supplemental feedings
after the first few months of breast-feeding, perhaps accounting for
the absence of a dose–response relationship. The reduction of risk
associated with breast-feeding is consistent with hypotheses
regarding incessant ovulation or ovarian inflammation, and with
the hypothesis regarding gonadotropin secretion, which is slowed
during breastfeeding (Harlow and Ephross, 1995). 
We found little evidence that menstrual factors or symptoms,
which may reflect ovulatory function and/or hormonal milieu,
influence ovarian cancer risk. In this study, consistent with most
previous studies (for example, Franceschi et al, 1991; Chen et al,
1992; Whittemore et al, 1992; Hankinson et al, 1995; Purdie et al,
1995; Salazar-Martinez, 1999), menarcheal age was unrelated to
risk overall. However, our findings indicated that increasing age at
menarche was associated with reduced risk among premenopausal
women; similarly, at least two previous studies have found a
stronger association between late menarcheal age and reduced risk
among younger women (Parazzini et al, 1989; Whittemore, 1993).
These findings may reflect the better recall of menarcheal age
among younger/premenopausal women, although age at menarche
is reported with reasonably good accuracy (Bean et al, 1979).
Early menarche is associated with a more rapid onset of ovulatory
cycles, and with the tendency to sustain higher levels of luteal
phase estradiol and progesterone (Vihko and Apter, 1984). Thus,
a protective effect of late menarche, observed here in pre-
menopausal women, is consistent with hypotheses regarding
incessant ovulation (Fathalla, 1971; Casagrande et al, 1979) and
ovarian inflammation (Ness and Cottreau, 1999), but inconsistent
with the hypothesis that higher levels of progesterone are associ-
ated with reduced risk (Risch, 1998). Similar to most previous
reports (for example, Cramer et al, 1983; Hartge et al, 1988; Chen
et al, 1992), we found no evidence of an association between age
at natural menopause and ovarian cancer risk. The lack of an 
association between risk and age at natural menopause, which 
is recalled with reasonable accuracy (Bean et al, 1979), reduces
the plausibility of hypotheses involving ovulatory events, or
ovulation-associated ovarian inflammation. 
In this study, as in most previous studies (Cramer et al, Chen
1983; et al, 1992; Purdie et al, 1995), ovarian cancer risk was not
influenced by patterns or characteristics of the menstrual cycle.
Although one previous study suggested an association between
heavier menstrual bleeding and increased risk (Purdie et al, 1995),
we found no effect for the duration or the heaviness of menstrual
bleeding. While our results suggest that cycle characteristics are
unrelated to risk, such factors are poorly recalled (Bean et al,
1979; Harlow and Ephross, 1995), and errors of self-report may
have attenuated underlying effects. In our data, there was no asso-
ciation between the type of sanitary product used during menstrua-
tion and ovarian cancer risk. 
In this study, consistent with previous reports (Cramer et al,
1983; McGowan et al, 1988; Chen et al, 1992; Purdie et al, 1995),
menstrual symptoms were largely unrelated to ovarian cancer risk.
However, we found preliminary evidence of reduced risk associ-
ated with insomnia occurring in conjunction with the menstrual
cycle, which to our knowledge has not been previously reported.
Oestrogen levels are likely to be lower, on average, in women who
experience insomnia (Empson and Purdie, 1999). Thus, our720 L Titus-Ernstoff et al
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finding of decreased risk associated with insomnia, while prelim-
inary, may reflect disparate hormonal milieus for case and control
women. 
Because of the large size of our study, we were able to evaluate
menstrual and reproductive factors in relation to the major tumour
histologic subtypes. Risk of all the tumour histologic subtypes was
uniformly reduced for parous women, relative to nulliparas.
However, we found no evidence that increasing parity was as-
sociated with decreased risk of mucinous tumours, whereas signif-
icant inverse trends were observed for serous invasive and
endometrioid/clear cell tumours. Similar results were found in a
case-control study conducted in Canada (Risch, 1996), and in a
retrospective cohort study conducted in Norway (Kvale et al,
1988). 
Our tumour subtype analyses showed that the influence of age
at first birth was limited to serous borderline and endo-
metrioid/clear cell tumours; age at last birth was associated only
with endometrioid/clear cell tumours. No effects of age at first
birth on risk of the tumour subtypes were observed in the
Norwegian or the Canadian study. In our study, breast-feeding and
average duration of breast-feeding were significantly associated
only with endometrioid/clear cell tumours. In the Canadian study,
the association between duration of breast-feeding and risk of
endometrioid tumours was marginally significant, whereas a
significant relationship was noted for serous invasive tumours
(Risch, 1996). Breast-feeding was not evaluated in the Norwegian
study. 
In our data, increased age at menarche was not associated with
decreased risk of any of the tumour subtypes. However, a menar-
cheal age of 16 years or more was associated with a dramatic
reduction in risk of endometrioid/clear cell tumours. Menstrual
factors were not assessed in the Canadian study, but the Norwegian
study found significant effects for menarcheal age of 17 or more in
relation to mucinous tumours. Consistent with the results of the
Norwegian study (Kvale et al, 1988), we found no evidence that
natural menopause was associated with any of the tumour
subtypes. 
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